RAPP (Rapport Therapeutics) FCF Margin %: -65.74% (As of Mar. 2026)


RAPP Rapport Therapeutics Inc RAPP
14 GF Score
Price $41.79
! 3 Warning Signs
View Full Analysis

What is Rapport Therapeutics FCF Margin %?

Rapport Therapeutics RAPP -0.60% 14 FCF Margin % is -65.74% as of Mar. 2026. GuruFocus rates RAPP with a GF Score™ of 14/100. The stock has 3 warning signs investors should review. Among 949 Biotechnology companies, Rapport Therapeutics ranks worse than 68.91% on this metric.

FCF Margin % is calculated as Free Cash Flow divided by its Revenue. Rapport Therapeutics's Free Cash Flow for the three months ended in Mar. 2026 was $-13.15 Mil. Rapport Therapeutics's Revenue for the three months ended in Mar. 2026 was $20.00 Mil. Therefore, Rapport Therapeutics's FCF Margin % for the quarter that ended in Mar. 2026 was -65.74%.

As of today, Rapport Therapeutics's current FCF Yield % is -4.04%.

The historical rank and industry rank for Rapport Therapeutics's FCF Margin % or its related term are showing as below:

RAPP' s FCF Margin % Range Over the Past 10 Years
Min: -403.54   Med: 0   Max: 0
Current: -403.54

RAPP's FCF Margin % is ranked worse than
68.91% of 949 companies
in the Biotechnology industry
Industry Median: -82.65 vs RAPP: -403.54

Rapport Therapeutics FCF Margin % Related Terms

Rapport Therapeutics FCF Margin % Historical Data

* Premium members only.

The historical data trend for Rapport Therapeutics's FCF Margin % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Rapport Therapeutics FCF Margin % Chart

Rapport Therapeutics Annual Data
Trend Dec22 Dec23 Dec24 Dec25
FCF Margin %
0.00 0.00 0.00 0.00

Rapport Therapeutics Quarterly Data
Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
FCF Margin % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 -65.74

RAPP vs SION, TYRA, IOVA: FCF Margin % Comparison

For the Biotechnology subindustry, Rapport Therapeutics's FCF Margin %, along with its competitors' market caps and FCF Margin % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rapport Therapeutics FCF Margin % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rapport Therapeutics's FCF Margin % distribution charts can be found below:

* The bar in red indicates where Rapport Therapeutics's FCF Margin % falls into.


RAPP
14GF Score
Rapport Therapeutics Inc RAPP
FCF Margin % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Rapport Therapeutics FCF Margin % Calculation

FCF margin is the ratio of Free Cash Flow divided by net sales or Revenue, usually presented in percent.

Rapport Therapeutics's FCF Margin for the fiscal year that ended in Dec. 2025 is calculated as

FCF Margin=Free Cash Flow (A: Dec. 2025 )/Revenue (A: Dec. 2025 )
=-88.089/0
= %

Rapport Therapeutics's FCF Margin for the quarter that ended in Mar. 2026 is calculated as

FCF Margin=Free Cash Flow (Q: Mar. 2026 )/Revenue (Q: Mar. 2026 )
=-13.147/20
=-65.74 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about FCF Margin % →
What does a FCF Margin % of -65.74% mean?
Rapport Therapeutics (RAPP) has a FCF Margin % of -65.74% as of Mar. 2026. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rapport Therapeutics and its competitors. According to the industry distribution chart, Rapport Therapeutics ranks #654 out of 949 companies in the Biotechnology industry, placing it in the top 68.9%.
Is Rapport Therapeutics' FCF Margin % too high?
Rapport Therapeutics' current FCF Margin % is -65.74%. Based on the distribution chart, Rapport Therapeutics ranks #654 out of 949 companies in the Biotechnology industry, which is below the industry midpoint. Overall, Rapport Therapeutics has a GF Score™ of 14/100, reflecting its overall financial health beyond just this single metric.
How does Rapport Therapeutics' FCF Margin % compare to SION and TYRA?
According to the Biotechnology industry distribution chart, Rapport Therapeutics ranks #654 out of 949 companies for FCF Margin %. This places Rapport Therapeutics in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good FCF Margin % for a Biotechnology company?
A good FCF Margin % depends on the Biotechnology industry context. However, FCF Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high FCF Margin % mean?
A high FCF Margin % can signal that a stock is expensive relative to its fundamentals. Free cash flow margin is the ratio of total free cash flow to net sales. View historical data on Rapport Therapeutics and its competitors. Rapport Therapeutics's current FCF Margin % is -65.74%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Rapport Therapeutics stock overvalued right now?
Rapport Therapeutics (RAPP) has a current FCF Margin % of -65.74%. The current FCF Margin % is -65.74%. Rapport Therapeutics' overall GF Score™ is 14/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is FCF Margin % calculated?
FCF Margin % is calculated from a company's financial statements. For Rapport Therapeutics (RAPP), the current FCF Margin % is -65.74% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Rapport Therapeutics Business Description

Address 99 High Street, Suite 2100, Boston, MA, USA, 02110
Rapport Therapeutics Inc is a clinical-stage biotechnology company dedicated to the discovery and development of small-molecule precision medicines for patients with neurological or psychiatric disorders. The company's portfolio of programs from its RAP technology platform includes RAP-219, an investigational small molecule being developed as a therapy for focal onset seizures, primary generalized tonic-clonic seizures, and bipolar mania. Additionally, it has two discovery-stage nicotinic acetylcholine receptor (nAChR) programs stemming from its RAP technology platform: one being developed for the treatment of chronic pain, and the second, being developed for the treatment of hearing disorders. Geographically, the company operates in the United States.
14GF Score

Get the complete analysis for RAPP

FCF Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$41.79
Price